EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model

Thursday, October 23, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

ROCKVILLE, Md., Oct. 23 EntreMed, Inc.(Nasdaq: ENMD), a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases, todayannounced the presentation of preclinical data for its Aurora A/angiogenesiskinase inhibitor, ENMD-2076. The data were presented by John Tentler, Ph.D.,Division of Medical Oncology, University of Colorado, at the 20thEORTC-NCI-AACR Annual Meeting being held this week in Geneva, Switzerland.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

ENMD-2076 is a novel kinase inhibitor with potent activity against AuroraA and a number of tyrosine kinases linked to cancer and inflammatory diseases.ENMD-2076 demonstrated strong antitumor effects in a xenograft model of humancolon cancer. Tumor stasis was seen at dose levels of 100 mg/kg/day, andtumor regression was observed at doses of 200 mg/kg ENMD-2076 per day. Dynamiccontrast-enhanced magnetic resonance imaging (DCE-MRI) and post-studyhistological examination of tumors suggest that the antitumor effects ofENMD-2076 are exerted through a combination of antiangiogenic andantiproliferative actions. Further analysis using positron emission tomography(PET) demonstrated a substantial decrease in tumor metabolic activity inanimals treated with ENMD-2076.

ENMD-2076 exerts its effects through multiple mechanisms of action,including antiproliferative activity and the inhibition of angiogenesis.ENMD-2076 has demonstrated substantial dose-dependent efficacy as a singleagent, including tumor regression, in multiple xenograft models (e.g. breast,colon, leukemia). Aurora kinases are key regulators of the process of mitosis,or cell division, and are often over-expressed in human cancers. In additionto the Aurora A isoform, ENMD-2076 has been shown to inhibit a distinctprofile of angiogenic tyrosine kinase targets. ENMD-2076 is currently in aphase 1 clinical study in advanced cancer patients.

Dr. Mark R. Bray, Vice President Research at EntreMed commented on thepresentation, "The exciting work presented by Dr. Tentler and his colleaguesunderscores the exceptional promise of ENMD-2076 as a novel anticancertherapeutic. Advanced non-invasive imaging using PET and DCE-MRI greatlyincreased the ability to monitor the antiangiogenic and antiproliferativemechanisms of ENMD-2076. We anticipate employing these techniques in upcomingENMD-2076 clinical trials. EntreMed is actively pursing development partnersfor this novel oral anticancer drug candidate."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developingtherapeutic candidates primarily for the treatment of cancer and inflammation.MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, iscurrently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novelantimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1studies in advanced cancers. The Company also has an approved IND applicationfor Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop andcommercialize new compounds based on the Company's expertise in angiogenesis,cell cycle regulation, cell signaling and inflammation -- processes vital tothe treatment of cancer and other diseases, such as rheumatoid arthritis.Additional information about EntreMed is available on the Company's web siteat www.entremed.com and in various filings with the Securities and ExchangeCommission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of thePrivate Securities Litigation Reform Act with respect to the outlook forexpectations for future financial or business performance (including thetiming of royalty revenues and future R&D expenditures), strategies,expectations and goals. Forward-looking statements are subject to numerousassumptions, risks and uncertainties, which change over time. Forward-lookingstatements speak only as of the date they are made, and no duty to updateforward-looking statements is assumed. Actual results could differ materiallyfrom those currently anticipated due to a number of factors, including thoseset forth in Securities and Exchange Commission filings under "Risk Factors,"including risks relating to the need for additional capital and theuncertainty of additional funding; variations in actual sales of Thalomid(R),risks associated with the Company's product candidates; the early-stageproducts under development; results in preclinical models are not necessarilyindicative of clinical results, uncertainties relating to preclinical andclinical trials; success in the clinical development of any products;dependence on third parties; future capital needs; and risks relating to thecommercialization, if any, of the Company's proposed products (such asmarketing, safety, regulatory, patent, product liability, supply, competitionand other risks).CONTACT: Ginny Dunn Associate Director, Corporate Communications & Investor Relations EntreMed, Inc. 240.864.2643

SOURCE EntreMed, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store